Consequently, while triple agonists represent an important advancement in obesity pharmacotherapy, their safety, tolerability, and long-term developmental effects in adolescents remain unknown
Answer: In a 48-week phase 2 trial, participants on the highest retatrutide doses lost up to roughly 24 percent of body weight, a figure that exceeded results reported for currently approved single and dual agonists
Take-Aways: 1) GLP-1s do not directly make anyone dizzy
We focus on your long-term health not quick fixes
Adjustment of Other Medications: Providers lower the glimepiride dose to 1 mg once daily to reduce the risk of hypoglycemia
Berman will conduct a thorough review of your health history, including your cardiovascular health, blood pressure, and any medications youre currently taking